Back to top
more

Semler Scientific (SMLR)

(Delayed Data from NSDQ)

$22.92 USD

22.92
59,220

-0.04 (-0.17%)

Updated May 10, 2024 04:00 PM ET

After-Market: $22.90 -0.02 (-0.09%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (95 out of 250)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Thermo Fisher (TMO) Introduces New Automated Enzyme Analyzers

The two new Gallery Enzyme Master systems by Thermo Fisher (TMO) offer enhanced reliable enzyme analysis across several enterprises.

Thermo Fisher's (TMO) Oncomine Dx Gets CDx Approval for EXKIVITY

Thermo Fisher (TMO) gains FDA pre-market approval for Oncomine Dx as companion diagnostic for Takeda's EXKIVITY.

Thermo Fisher's (TMO) Oncomine Dx Gets CDx Approval From MHLW

Thermo Fisher's (TMO) Oncomine Dx Target Test has been approved by MHLW as a companion diagnostic for Eli Lilly and Company's selpercatinib.

Here's Why You Should Add STERIS (STE) to Your Portfolio Now

STERIS (STE) ended first-quarter fiscal 2022 with better-than-expected results and strong segmental performance, driving the top line.

Zimmer Biomet (ZBH) Hurt by EMEA's Slow Recovery Amid Pandemic

Zimmer Biomet's (ZBH) leveraged capital structure is an added concern.

Thermo Fisher (TMO) Gains Government Contract for Pipette Tip

Thermo Fisher (TMO) will co-invest with the U.S. government to build a new manufacturing center for pipette tips in North Carolina.

Here's Why You Should Retain Integra (IART) Stock for Now

Solid performance across the CSS and Tissue Technologies segments is driving the top line for Integra (IART).

Thermo Fisher's (TMO) Oncomine Dx Gets CDx Approval for TIBSOVO

Thermo Fisher (TMO) receives FDA go-ahead for the Oncomine Dx Target Test as a CDx for Servier's ivosidenib tablets, TIBSOVO.

SmileDirectClub (SDC) Reels Under Rising Costs, Debt Woes

SmileDirectClub (SDC) sees net operating cash outflow in the second quarter.

Teleflex (TFX) Rides on UroLift Growth, Hurt by Pandemic Woes

Teleflex (TFX) has decided to increase its investment in 2021 and run a national campaign for the full year.

Globus Medical (GMED) Gets FDA Nod for Excelsius3D

The receipt of FDA's 510(k) clearance for Globus Medical's (GMED) Excelsius3D is expected to expand the company's presence in the intraoperative imaging system space.

Insulet's (PODD) Omnipod Gets FDA Nod for Use With Lyumjev

Insulet's (PODD) Omnipod is the only insulin pump to get approved for use with Lyumjev in the United States.

Amedisys (AMED) Suffers From Low Occupancy Amid Pandemic

The prolonged and lingering impact of COVID-19 on Amedisys (AMED) Hospice business has hampered its ability to grow at the earlier-projected rates.

Thermo Fisher (TMO) Hits a 52-Week High: What's Driving It?

Strong performance by the four reported business segments is driving the top line for Thermo Fisher (TMO).

Semler Scientific Inc. (SMLR) Q2 Earnings Top Estimates

Semler Scientific Inc. (SMLR) delivered earnings and revenue surprises of 36.07% and -1.51%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Semler Scientific Inc. (SMLR) Reports Next Week: Wall Street Expects Earnings Growth

Semler Scientific Inc. (SMLR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Semler Scientific Inc. (SMLR) Soars 4.2%: Is Further Upside Left in the Stock?

Semler Scientific Inc. (SMLR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Orthofix (OFIX) Launches FORZA Ti PLIF Spacer System in the US

Orthofix (OFIX) launches FORZA Ti PLIF Spacer System to improve posterior lumbar interbody fusion procedures in the United States.

What Makes Semler Scientific Inc. (SMLR) a New Buy Stock

Semler Scientific Inc. (SMLR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

3 Reasons Why Semler Scientific Inc. (SMLR) Is a Great Growth Stock

Semler Scientific Inc. (SMLR) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Orthofix (OFIX) Launches OSCAR PRO System in the US & Europe

Orthofix's (OFIX) latest innovation is expected to drive organic growth in its Global Orthopedics business.

3 Reasons Growth Investors Will Love Semler Scientific Inc. (SMLR)

Semler Scientific Inc. (SMLR) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Semler Scientific Inc. (SMLR) Q1 Earnings and Revenues Top Estimates

Semler Scientific Inc. (SMLR) delivered earnings and revenue surprises of 22.45% and 10.32%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

3 Reasons Why Semler Scientific Inc. (SMLR) Is a Great Growth Stock

Semler Scientific Inc. (SMLR) could produce exceptional returns because of its solid growth attributes.

Omnicell (OMCL) Q1 Earnings Beat Estimates, Margins Expand

Omnicell's (OMCL) raises adjusted EPS guidance for 2021 , which buoys optimism.